(1 - 20 of 39)

Pages

document
Haas, F.J.L.M. (author), Kluft, C. (author), Biesma, D.H. (author), Schutgens, R.E.G. (author)
The objective of the present study was to evaluate the influence of thrombophilia risk factors on variables of a chromogenic thrombin generation assay (ETP) in a setting with acute deep venous thrombosis (DVT) and non-DVT patients. In 152 outpatients suspected for DVT, the results of thrombophilia investigations were known. In all patients,...
article 2011
document
Norris, L.A. (author), Brosnan, J. (author), Bonnar, J. (author), Conard, J. (author), Kluft, C. (author), Hellgren, M. (author), TNO Kwaliteit van Leven (author)
Epidemiological studies have shown that hormone therapy (HT) increases the risk of venous thromboembolism in post menopausal women. The mechanism of this increased risk is unknown; however, activation of the haemostatic system is known to contribute to the pathogenesis of venous thromboembolism. In post-menopausal women the estrogen /progestogen...
article 2008
document
de Lange, M. (author), de Geus, E.J.C. (author), Kluft, C. (author), Meijer, P. (author), van Doornen, L.J.P. (author), Boomsma, D.I. (author), Snieder, H. (author), TNO Kwaliteit van Leven (author)
Differences in genetic influence on death from CHD between males and females have been reported. Haemostatic factors have consistently been associated with risk for coronary heart disease (CHD), but sex differences in genetic architecture have not been studied. This study in middle-aged twins investigates whether there are sex differences in...
article 2006
document
Witte, D.R. (author), Broekmans, W.M.R. (author), Kardinaal, A.F.M. (author), Klöpping-Ketelaars, I.A.A. (author), van Poppel, G. (author), Bots, M.L. (author), Kluft, C. (author), Princen, J.M.G. (author), Centraal Instituut voor Voedingsonderzoek TNO TNO Voeding (author)
Background: Flow mediated dilatation (FMD) of the brachial artery and soluble intercellular adhesion molecule 1 (sICAM-1) are measures of distinct functions of the endothelium, reflecting nitric oxide (NO)-mediated and pro-inflammatory status, respectively. The comparative value of the two measures in relation to cardiovascular risk is unknown....
article 2003
document
Rosén, S. (author), Wejkum, L. (author), Billing-Claeson, S. (author), Ghosh, R. (author), Grdic, K. (author), Chmielewska, J. (author), Meijer, P. (author), Kluft, C. (author), Tengborn, L. (author), Conkie, J. (author), Walker, I. (author), Gaubius Instituut TNO (author)
A chromogenic bioimmunoassay method for determination of t-PA activities has been evaluated on plasmas from healthy individuals and from thromboembolic patients. The assay consists of an initial binding and washing step, whereby plasma t-PA is bound to a specific monoclonal t-PA antibody, which is coated on to microplate wells, followed by a...
article 1998
document
de Maat, M.P.M. (author), Haverkate, F. (author), Kluft, C. (author), Gaubius Instituut TNO (author)
On October 1, 1997, a 1 day hot-topic workshop on C-reactive protein (CRP) was organized in Leiden, the Netherlands, aiming at further evaluating the importance of inflammation as a critical mechanism in cardiovascular disease. C-reactive protein (CRP) is an acute phase protein that is associated with risk of cardiovascular events in healthy...
article 1998
document
Leebeek, F.W.G. (author), Los, P. (author), Kluft, C. (author), Gaubius Instituut TNO (author)
We have studied the plasminogen-binding and non-binding molecular forms of α2-antiplasmin (α2-AP), the major inhibitor of plasmin, using a modification of the crossed immunoelectrophoresis technique (mCIE). The previous technique using addition of Lys-plasminogen to the gel of the first dimension electrophoresis was simplified using commercially...
article 1996
document
Bots, M.L. (author), van der Bom, J.G. (author), Haverkate, F. (author), Meijer, P. (author), Hofman, A. (author), Grobbee, D.E. (author), Kluft, C. (author), TNO Preventie en Gezondheid (author)
Background and objective. A low activated protein C (APC) response increases the risk of venous thrombosis, and possibly arterial disease. Apart from the factor V Leiden mutation, other factors may determine the level of APC response. In most studies on the association with arterial disease, cardiovascular risk factors were not appropriately...
article 1996
document
Clason, S.B. (author), Meijer, P. (author), Kluft, C. (author), Ersdal, E. (author), Gaubius Instituut TNO (author)
A new automated method, COAMATIC® Plasmin Inhibitor, provides a tool for specific determination of Plasmin Inhibitor activity in plasma. The method is adapted to the ACL 300R, Cobas Mira, MLA 1000C and to the Thrombolyzer. Low plasmin concentrations combined with short incubation times ensure good specificity also in the low range, resulting in...
article 1996
document
Iacoviello, L. (author), di Castelnuovo, A. (author), de Knijff, P. (author), d' Orazio, A. (author), Amore, C. (author), Kluft, C. (author), Donati, M.B. (author), Gaubius Instituut TNO (author)
Several authors have suggested that increased t-PA antigen levels were associated to thrombotic events in coronary, cerebral and peripheral arteries. Baseline and stimulated levels of t-PA in plasma appear highly heritable, therefore, it could be of interest to evaluate the role of genetic variations in the t-PA locus in determining its plasma...
article 1996
document
Kluft, C. (author), Meijer, P. (author), Gaubius Laboratory, TNO-PG, Leiden, Netherlands TNO Preventie en Gezondheid (author)
Procedures of blood collection and handling can be different for the various variables in fibrinolysis. Some of them may require adaptation to the progress in assay methodology and in biochemical and physiological knowledge. During the Leiden Fibrinolysis Workshop 6 in 1996, the procedures described in 1990 for tissue-type plasminogen activator ...
article 1996
document
Gram, J. (author), Jespersen, J. (author), Kluft, C. (author), Declerck, P. (author), Gaubius Instituut TNO (author)
Biochemical measurements of quantities, i.e. analytes, of the haemostatic system are the basis of evaluating patients with potentially serious or lifethreatening disorders. Therefore, there is a need of a high level of certainty of the results. Experience based on the comprehensive international standardization of prothrombin time measurements ...
article 1996
document
Huisman, L.G.M. (author), van Griensven, J.M.T. (author), Kluft, C. (author), TNO Preventie en Gezondheid (author)
Standardisation of t-PA antigen and activity assays requires a t-PA standard which ideally is a single preparation suitable for all assays. Most t-PA preparations, however, are not homogeneous; they can contain several forms of t-PA: single-chain and two-chain t-PA, and two glycoforms (I and II). In this study, the behaviour of Actilyse...
article 1996
document
Biasucci, L.M. (author), de Maat, M.P.M. (author), Meo, A. (author), van der Greet, W. (author), Summaria, F. (author), Quaranta, G. (author), Liuzzo, G. (author), Kluft, C. (author), Maseri, A. (author), Gaubius Instituut TNO (author)
In order to investigate the role of the hemostatic, fibrinolytic and inflammatory system in unstable angina, we assessed the levels of thrombin-antithrombin III (TAT), Prothrombin Fragment 1+2 (F1+2), plasmin-antiplasmin (PAP) and D-Dimer (DD) and of C-reactive protein (CRP) in 51 patients admitted to our CCU with severe unstable angina. Thirty...
article 1996
document
Heijmans, B.T. (author), Kluft, C. (author), Bots, M.L. (author), Lagaay, A.M. (author), Brand, A. (author), Grobbee, D.E. (author), Knook, D.L. (author), Slagboom, P.E. (author), Gaubius Instituut TNO (author)
The genetic component of human longevity is estimated at 30%. Which genes are involved in determining human longevity, however, is largely unknown. Genes that may affect human survival are susceptibility loci for major age related pathologies. Many studies are being performed to identify such loci for cardiovascular disease, dementia and...
article 1996
document
de Maat, M.P.M. (author), de Knijff, P. (author), Green, F.R. (author), Thomas, A.E. (author), Jespersen, J. (author), Kluft, C. (author), TNO Preventie en Gezondheid (author)
Elevated plasma fibrinogen levels represent an increased risk for cardiovascular diseased, but the mechanism explaining this association is still not clear. Genetic differences may play a role, because it has been shown that individuals who carry the rare alleles of polymorphisms in the genes for the Bβ-chain (Bcl I and G/A 455) and the Aα-chain...
article 1995
document
Hennis, B.C. (author), Boomsma, D.I. (author), Fijnvandraat, K. (author), Gevers Leuven, J.A. (author), Peters, M. (author), Kluft, C. (author), Gaubius Instituut TNO (author)
Plasma levels of histidine-rich glycoprotein (HRG) were investigated in three groups of women receiving a different dose of estrogens. First, the effect of low-dose estrogen was studied in a group of 83 postmenopausal women who were treated with 0.625 mg conjugated estrogens (CE). No significant change from baseline levels was found at the end...
article 1995
document
Hennis, B.C. (author), van Boheemen, P.A. (author), Koeleman, B.P.C. (author), Boomsma, D.I. (author), Engesser, L. (author), van Wees, A.G.M. (author), Novakova, I. (author), Brommer, E.J.P. (author), Kluft, C. (author), Gaubius Instituut TNO (author)
Recent studies describe families with both elevated plasma HRG levels and thrombosis. In order to study the possibility that allelic variants of the HRG locus are associated with differences in HRG level, we studied linkage between HRG levels and a dinucleotide repeat polymorphism in a Dutch family which was selected on the presence of both...
article 1995
document
Dooijewaard, G. (author), van Boheemen, P.A. (author), Binnema, D.J. (author), Kluft, C. (author), Gaubius Laboratory, VVO-TNO, PO Box 430, 2300 AK Leiden, Instituut voor verouderings- en vaatziekten onderzoek TNO (author)
Chemicals/CAS: Tissue Plasminogen Activator, EC 3.4.21.68; Urinary Plasminogen Activator, EC 3.4.21.73
article 1992
document
Kluft, C. (author), Gaubius Instituut TNO (author)
Chemicals/CAS: blood clotting factor 12, 9001-30-3; high molecular weight kininogen, 97792-85-3; plasminogen activator, 9039-53-6; prekallikrein, 9055-02-1; tissue plasminogen activator, 105913-11-9; urokinase, 139639-24-0; Factor XII, 9001-30-3; Kininogens; Prekallikrein, 9055-02-1
article 1992
(1 - 20 of 39)

Pages